What is the fair value of Akebia Ther (NASDAQ-AKBA) stock?

The current fair value estimate for Akebia Ther (NASDAQ-AKBA) is $0.96. This implies an estimated upside of 4.5% versus the current market price.

Is Akebia Ther (NASDAQ-AKBA) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.5% versus the current market price.

What is the analyst price target for NASDAQ-AKBA stock?

The available analyst price target for Akebia Ther (NASDAQ-AKBA) is $3.92. The analyst target implies estimated upside of 327.6%.

How is the financial health of Akebia Ther?

The current financial health read for Akebia Ther (NASDAQ-AKBA) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Akebia Ther's next earnings date?

The next earnings date currently listed for Akebia Ther (NASDAQ-AKBA) is October 29, 2026.

Does Akebia Ther (NASDAQ-AKBA) pay dividends?

The latest available data indicates no current dividend yield for Akebia Ther (NASDAQ-AKBA).

What is the market capitalization of Akebia Ther?

The current market capitalization listed for Akebia Ther is 253.7 M.

What is the enterprise value of Akebia Ther?

The current enterprise value listed for Akebia Ther is 291.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Akebia Ther?

The ticker symbol for Akebia Ther is NASDAQ-AKBA, and the stock is listed on NASDAQ.

Where is Akebia Ther (NASDAQ-AKBA) listed?

Akebia Ther (NASDAQ-AKBA) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Akebia Ther?

The current debt-to-total-capital ratio listed for Akebia Ther is 44.5%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Akebia Ther?

The free float listed for Akebia Ther is 97.7%. Free float helps investors understand how much of the share base is available for public trading.

Akebia Ther (AKBA) Fair Value & Stock Analysis

Akebia Ther (AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people with kidney diseases. Its commercial portfolio includes Vafseo (vadadustat), an oral therapy for anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis-dependent patients, and Auryxia, a ferric citrate product used to help control serum phosphorus in adults with dialysis-dependent CKD and to treat iron deficiency anemia in adults with non-dialysis-dependent CKD. The company is also advancing AKB-9090, which is in Phase 2 testing for cardiac surgery-related acute kidney injury and acute respiratory distress syndrome, as well as AKB-10108 for retinopathy of prematurity in neonates. Akebia has licensing and collaboration arrangements with partners including Tanabe Pharma Corporation, CSL Vifor, Averoa, Panion & BF Biotech, Cyclerion Therapeutics, and Q32. Founded in 2007 and based in Cambridge, Massachusetts, Akebia Therapeutics trades as common stock on Nasdaq under the ticker AKBA.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-AKBA	$0.96	4.5% Upside	Fair	$3.92	327.6% Upside	Bargain	Good	0.0%	October 29, 2026	9.9x	1.1x	253.7 M	291.9 M	44.5%	97.7%	-6.8	-135.7%